风湿与肌肉骨骼疾病中SARS-CoV-2感染及疫苗接种的风险与预后:为EULAR推荐提供依据的系统文献综述
该系统文献综述检索至2021年5月31日,纳入208项研究(90项通过质量评估),评估风湿与肌肉骨骼疾病(RMD)患者SARS-CoV-2感染风险、COVID-19预后及疫苗免疫原性。多数研究偏倚风险不明确或高;RMD患者感染风险及COVID-19预后与无RMD者总体无更多风险,但疾病活动度、糖皮质激素、利妥昔单抗与更差预后相关,疫苗接种一般具有免疫原性但抗体反应低于对照。
要点
- RMD患者感染SARS-CoV-2风险及COVID-19预后与无RMD者总体无更多风险
- 疾病活动度与更差COVID-19预后相关,可能解释糖皮质激素使用的风险增加
- 利妥昔单抗与更差COVID-19预后相关,JAK抑制剂可能相关
核心结论
- RMD患者感染SARS-CoV-2风险及COVID-19预后与无RMD者总体无更多风险。
- 疾病活动度与更差COVID-19预后相关,可能解释糖皮质激素使用所见的风险增加。
- 利妥昔单抗与更差COVID-19预后相关,JAK抑制剂可能相关。
- 疫苗接种一般具有免疫原性,但抗体反应低于对照,且与高龄、利妥昔单抗及霉酚酸负相关。
研究设计与样本
- 系统文献综述,检索截至2021年5月31日,纳入对照试验和观察性研究。
- 共筛选5165条记录,纳入208项研究,其中90项通过质量评估并提取数据:发病率42项、危险因素42项、疫苗接种14项。
- 质量评估要求提供合适的COVID-19病例定义,以及基础发病率或对照组(>10例结局事件且风险估计至少校正年龄、性别和合并症)。
- 多数研究偏倚风险不明确或高。
主要发现
- RMD患者感染SARS-CoV-2风险(26项研究)或COVID-19预后(14项研究)与无RMD者相比总体无更多风险。
- 不同RMD之间发生(重症)COVID-19风险无一致差异(19项研究)。
- 疾病活动度与更差COVID-19预后相关(2项研究)。
- 糖皮质激素使用与更差COVID-19预后相关(13项研究),可能由疾病活动度解释。
- 利妥昔单抗与更差COVID-19预后相关(7项研究),JAK抑制剂可能相关(3项研究)。
关键数值与推荐
- 疫苗接种一般具有免疫原性,但抗体反应低于对照。
- 疫苗免疫原性与高龄、利妥昔单抗及霉酚酸负相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多数研究偏倚风险不明确或高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Perform a systematic literature review (SLR) on risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and musculoskeletal diseases (RMDs). METHODS: Literature was searched up to 31 May 2021, including (randomised) controlled trials and observational studies with patients with RMD. Pending quality assessment, data extraction was performed and risk of bias (RoB) was assessed. Quality assessment required provision of (1) an appropriate COVID-19 case definition, and (2a) a base incidence (for incidence data) or (2b) a comparator, >10 cases with the outcome and risk estimates minimally adjusted for age, sex and comorbidities (for risk factor data). RESULTS: Of 5165 records, 208 were included, of which 90 passed quality assessment and data were extracted for incidence (n=42), risk factor (n=42) or vaccination (n=14). Most studies had unclear/high RoB. Generally, patients with RMDs do not face more risk of contracting SARS-CoV-2 (n=26 studies) or worse prognosis of COVID-19 (n=14) than individuals without RMDs. No consistent differences in risk of developing (severe) COVID-19 were found between different RMDs (n=19). Disease activity is associated with worse COVID-19 prognosis (n=2), possibly explaining the increased risk seen for glucocorticoid use (n=13). Rituximab is associated with worse COVID-19 prognosis (n=7) and possibly Janus kinase inhibitors (n=3). Vaccination is generally immunogenic, though antibody responses are lower than in controls. Vaccine immunogenicity is negatively associated with older age, rituximab and mycophenolate. CONCLUSION: This SLR informed the July 2021 update of the European Alliance of Associations for Rheumatology recommendations for the management of RMDs in the context of SARS-CoV-2.
引用
- Kroon FPB, Najm A, Alunno A, et al. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. Ann Rheum Dis. 2021. PMID: 34876462. doi:10.1136/annrheumdis-2021-221575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。